CY1115236T1 - Ενωσεις για την προληψη και τη θεραπεια των καρδιαγγειακων παθησεων - Google Patents
Ενωσεις για την προληψη και τη θεραπεια των καρδιαγγειακων παθησεωνInfo
- Publication number
- CY1115236T1 CY1115236T1 CY20141100220T CY141100220T CY1115236T1 CY 1115236 T1 CY1115236 T1 CY 1115236T1 CY 20141100220 T CY20141100220 T CY 20141100220T CY 141100220 T CY141100220 T CY 141100220T CY 1115236 T1 CY1115236 T1 CY 1115236T1
- Authority
- CY
- Cyprus
- Prior art keywords
- prevention
- treatment
- unions
- heart diseases
- apoa
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title 1
- 102000005666 Apolipoprotein A-I Human genes 0.000 abstract 2
- 108010059886 Apolipoprotein A-I Proteins 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/02—1,2-Thiazines; Hydrogenated 1,2-thiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Η παρούσα κοινοποίηση αφορά σε ενώσεις, οι οποίες είναι χρήσιμες για ρύθμιση της έκφρασης της απολιποπρωτεΐνης Α-Ι (ΑpοΑ-Ι) και στη χρήση τους για τη θεραπεία και την πρόληψη της καρδιαγγειακής πάθησης και των συγγενών καταστάσεων ασθένειας, συμπεριλαμβανομένων των συγγενών με τη χοληστερόλη ή τα λιπίδια διαταραχών, όπως είναι, παραδείγματος χάριν, η αθηροσκλήρωση.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CA2007/000146 WO2008092231A1 (en) | 2007-02-01 | 2007-02-01 | Compounds for the prevention and treatment of cardiovascular diseases |
US11/670,238 US8053440B2 (en) | 2007-02-01 | 2007-02-01 | Compounds for the prevention and treatment of cardiovascular diseases |
EP07710597.1A EP2118074B1 (en) | 2007-02-01 | 2007-02-01 | Compounds for the prevention and treatment of cardiovascular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1115236T1 true CY1115236T1 (el) | 2017-01-04 |
Family
ID=51894355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20141100220T CY1115236T1 (el) | 2007-02-01 | 2014-03-21 | Ενωσεις για την προληψη και τη θεραπεια των καρδιαγγειακων παθησεων |
Country Status (17)
Country | Link |
---|---|
US (7) | US8053440B2 (el) |
EP (1) | EP2118074B1 (el) |
JP (1) | JP5236664B2 (el) |
KR (1) | KR101444489B1 (el) |
CN (1) | CN101641339B (el) |
AU (1) | AU2007345526B2 (el) |
CA (1) | CA2676984C (el) |
CY (1) | CY1115236T1 (el) |
DK (1) | DK2118074T3 (el) |
ES (1) | ES2454966T3 (el) |
HK (1) | HK1136283A1 (el) |
MX (1) | MX2009008099A (el) |
NZ (1) | NZ579355A (el) |
PL (1) | PL2118074T3 (el) |
PT (1) | PT2118074E (el) |
SI (1) | SI2118074T1 (el) |
WO (1) | WO2008092231A1 (el) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040033480A1 (en) * | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
EP2314295B1 (en) * | 2005-07-29 | 2015-01-28 | Resverlogix, Inc | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
US8053440B2 (en) | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
US20080255161A1 (en) * | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
US20090257979A1 (en) * | 2008-04-15 | 2009-10-15 | Intermune, Inc. | Novel Inhibitors of Hepatitis C Virus Replication |
PT2346837E (pt) * | 2008-06-26 | 2015-04-02 | Resverlogix Corp | Métodos de preparação de derivados de quinazolinona |
CN101628913B (zh) * | 2008-07-18 | 2013-01-23 | 中国科学院广州生物医药与健康研究院 | 用作雌激素相关受体调节剂的化合物及其应用 |
US8604049B2 (en) | 2008-08-05 | 2013-12-10 | Boehringer Ingelheim International Gmbh | 4-dimethylamino-phenyl-substituted naphthyridines, and use thereof as medicaments |
US20100267752A1 (en) * | 2008-10-15 | 2010-10-21 | Gilead Palo Alto, Inc. | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
WO2010061908A1 (ja) | 2008-11-28 | 2010-06-03 | 中外製薬株式会社 | 1-(2h)-イソキノロン誘導体 |
ES2542835T3 (es) * | 2009-01-08 | 2015-08-12 | Resverlogix Corporation | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
BRPI1009315B8 (pt) * | 2009-03-18 | 2021-05-25 | Resverlogix Corp | composto anti-flamatórios e suas composições farmacêuticas |
TR201818390T4 (tr) | 2009-04-22 | 2019-01-21 | Resverlogix Corp | Yeni̇ anti̇-i̇nflamatuvar ajanlar |
TW201121968A (en) * | 2009-11-09 | 2011-07-01 | Intermune Inc | Novel inhibitors of hepatitis C virus replication |
NZ600857A (en) * | 2010-01-29 | 2014-06-27 | Boehringer Ingelheim Int | Substituted naphthyridines and their use as syk kinase inhibitors |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
JP5830534B2 (ja) | 2010-07-09 | 2015-12-09 | ファイザー・リミテッドPfizer Limited | 化合物 |
EP2593432B1 (en) | 2010-07-12 | 2014-10-22 | Pfizer Limited | N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors |
US8772343B2 (en) | 2010-07-12 | 2014-07-08 | Pfizer Limited | Chemical compounds |
ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
CA2804716A1 (en) | 2010-07-12 | 2012-01-19 | Pfizer Limited | Chemical compounds |
EP2593431B1 (en) | 2010-07-12 | 2014-11-19 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
WO2012019093A1 (en) * | 2010-08-05 | 2012-02-09 | Human Biomolecular Research Institute | Synthetic compounds and methods to decrease nicotine self-administration |
MX336224B (es) | 2011-07-26 | 2016-01-12 | Boehringer Ingelheim Int | Quinolinas sustituidas y su uso como medicamentos. |
WO2013033270A2 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same |
WO2013033269A1 (en) | 2011-08-29 | 2013-03-07 | Coferon, Inc. | Bioorthogonal monomers capable of dimerizing and targeting bromodomains and methods of using same |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US8710064B2 (en) * | 2011-10-20 | 2014-04-29 | China Medical University | 2-aryl-4-quinazolinones and their pharmaceutical compositions |
PL2773354T3 (pl) | 2011-11-01 | 2019-12-31 | Resverlogix Corp. | Doustna formulacja o natychmiastowym uwalnianiu dla podstawowych chinazolinów |
CN102516169B (zh) * | 2011-12-31 | 2014-05-28 | 清华大学 | 制备多取代异喹啉及杂环并吡啶衍生物的方法 |
CN104302358B (zh) | 2012-03-07 | 2017-12-05 | 癌症研究协会:皇家癌症医院 | 3‑芳基‑5‑取代的异喹啉‑1‑酮化合物和它们的治疗用途 |
PL2882714T3 (pl) * | 2012-08-08 | 2020-02-28 | Merck Patent Gmbh | Pochodne (aza-)izochinolinonowe |
CA2886973C (en) | 2012-10-15 | 2017-08-15 | Albemarle Corporation | Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds |
NZ707276A (en) * | 2012-10-15 | 2016-02-26 | Resverlogix Corp | Compounds useful in the synthesis of benzamide compounds |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) * | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
US9675697B2 (en) | 2013-03-11 | 2017-06-13 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
US9636328B2 (en) | 2013-06-21 | 2017-05-02 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
BR112015031073B1 (pt) | 2013-06-21 | 2022-11-29 | Zenith Epigenetics Ltd | Compostos inibidores bicíclicos de bromodomínio e composição farmacêutica contendo os referidos compostos |
KR20160038008A (ko) * | 2013-07-31 | 2016-04-06 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 억제제로서 신규 퀴나졸리논 |
EP3035934A4 (en) * | 2013-08-21 | 2017-04-26 | Resverlogix Corp. | Compositions and therapeutic methods for accelerated plaque regression |
JP2016528276A (ja) * | 2013-08-21 | 2016-09-15 | レスバーロジックス コーポレイション | プラーク退縮を促進するための組成物及び治療法 |
AU2014320149A1 (en) | 2013-09-11 | 2016-04-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
US9771333B2 (en) * | 2013-11-20 | 2017-09-26 | Signalchem Lifesciences Corp. | Quinazoline derivatives as TAM family kinase inhibitors |
JP2017511801A (ja) | 2014-02-28 | 2017-04-27 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | BETブロモドメイン阻害剤としての9H−ピリミド[4,5−b]インドールおよび関連類似体 |
BR112016025470A2 (pt) | 2014-05-02 | 2017-08-15 | Cerenis Therapeutics Holding S A | ?hdl terapêutico? |
US10179125B2 (en) | 2014-12-01 | 2019-01-15 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
US10710992B2 (en) | 2014-12-01 | 2020-07-14 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
WO2016092375A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Substituted heterocycles as bromodomain inhibitors |
US10231953B2 (en) | 2014-12-17 | 2019-03-19 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
US10307407B2 (en) | 2015-02-27 | 2019-06-04 | The Regents Of The University Of Michigan | 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
WO2016196065A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Methods and compositions for assessing responsiveness of cancers to bet inhibitors |
JP2018526448A (ja) * | 2015-09-07 | 2018-09-13 | 浙江華海薬業股▲フン▼有限公司 | 一酸化窒素を放出可能なプロドラッグ分子 |
ES2882066T3 (es) | 2016-02-15 | 2021-12-01 | Univ Michigan Regents | 1,4-oxazepinas fusionadas y análogos relacionados como inhibidores de bromodominio BET |
WO2017176958A1 (en) | 2016-04-06 | 2017-10-12 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
BR112018070549A2 (pt) | 2016-04-06 | 2019-02-12 | The Regents Of The University Of Michigan | degradantes de proteína mdm2 |
US10633386B2 (en) | 2016-04-12 | 2020-04-28 | The Regents Of The University Of Michigan | BET protein degraders |
JP6961684B2 (ja) | 2016-09-13 | 2021-11-05 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Betタンパク質分解物質としての縮合1,4−オキサゼピン |
EP3858837A1 (en) | 2016-09-13 | 2021-08-04 | The Regents of The University of Michigan | Fused 1,4-diazepines as bet protein degraders |
RU2016138751A (ru) * | 2016-09-30 | 2018-04-02 | Общество с ограниченной ответственностью "Диборнол Девелопмент" | Средство для лечения сердечно-сосудистых заболеваний |
CN110049981A (zh) * | 2016-12-09 | 2019-07-23 | 苏州科睿思制药有限公司 | 一种溴结构域蛋白抑制剂药物的晶型及其制备方法和用途 |
JP7273723B2 (ja) * | 2016-12-20 | 2023-05-15 | オリゴメリックス インコーポレイテッド | タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法 |
JP7273722B2 (ja) | 2016-12-20 | 2023-05-15 | オリゴメリックス インコーポレイテッド | タウオリゴマーの形成を阻害する新規ベンゾフラン、ベンゾチオフェン及びインドール類似体並びにそれらの使用方法 |
US11046709B2 (en) | 2017-02-03 | 2021-06-29 | The Regents Of The University Of Michigan | Fused 1,4-diazepines as BET bromodomain inhibitors |
CN108069954B (zh) * | 2017-03-03 | 2018-11-23 | 上海华汇拓医药科技有限公司 | 含no供体的喹唑啉酮化合物 |
ES2681124B1 (es) * | 2017-03-08 | 2019-06-19 | Fund Imdea Alimentacion | Usos medicos de la apolipoproteina a y de activadores de la misma |
CN109384784B (zh) * | 2017-08-10 | 2021-01-12 | 浙江海正药业股份有限公司 | 磺酰胺类衍生物、其制备方法及其在医药上的用途 |
US11267822B2 (en) | 2017-09-13 | 2022-03-08 | The Regents Of The University Of Michigan | BET bromodomain protein degraders with cleavable linkers |
CN108484510B (zh) * | 2018-05-18 | 2020-05-05 | 东南大学 | 一种基于brd4抑制剂rvx-208的衍生物及其制备方法和应用 |
KR20210020889A (ko) | 2018-06-13 | 2021-02-24 | 디블라이 아게 | 응축된 트리아제핀 유도체의 제조 및 이의 bet 억제제로서 용도 |
US11618746B2 (en) | 2018-12-17 | 2023-04-04 | Vertex Pharmaceuticals Incorporated | Inhibitors of APOL1 and methods of using same |
CN109776413A (zh) * | 2019-01-29 | 2019-05-21 | 天津科技大学 | 一种具有降糖活性的异喹啉衍生物和应用 |
CN109897009B (zh) * | 2019-03-15 | 2022-06-28 | 深圳晶泰科技有限公司 | 一种Apabetalone水合物晶型及其制备方法 |
CN109824608B (zh) * | 2019-03-15 | 2022-06-21 | 深圳晶泰科技有限公司 | 一种Apabetalone晶型及其制备方法 |
AU2020377539A1 (en) | 2019-11-05 | 2022-05-19 | Resverlogix Corp. | Methods of treatment and/or prevention of major adverse cardiovascular events (mace) with a combination of a bet bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor |
KR102420263B1 (ko) * | 2019-11-26 | 2022-07-13 | 주식회사 베노바이오 | 신규한 퀴나졸린 리독스 유도체 및 bet 억제제로서의 용도 |
JP7483032B2 (ja) * | 2019-11-26 | 2024-05-14 | ベノビオ カンパニー リミテッド | 新規ケルセチンレドックス誘導体及びbet阻害剤としての用途 |
KR20220124736A (ko) * | 2020-01-08 | 2022-09-14 | 리스버로직스 코퍼레이션 | Bet 브로모도메인 억제제 및 디펩티딜 펩티다아제 4 억제제의 조합을 이용해 주요 심혈관 이상 반응(mace)을 치료 및/또는 예방하는 방법 |
KR20220151634A (ko) | 2020-03-06 | 2022-11-15 | 버텍스 파마슈티칼스 인코포레이티드 | Apol-1 의존성 국소 분절성 사구체경화증을 치료하는 방법 |
WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
TW202216713A (zh) | 2020-07-02 | 2022-05-01 | 美商英塞特公司 | 作為jak2 v617f抑制劑之三環脲化合物 |
CA3190609A1 (en) | 2020-08-26 | 2022-03-03 | Vertex Pharmaceuticals Incorporated | Inhibitors of apol1 and methods of using same |
WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
US11958861B2 (en) | 2021-02-25 | 2024-04-16 | Incyte Corporation | Spirocyclic lactams as JAK2 V617F inhibitors |
CN115710202B (zh) * | 2021-08-23 | 2024-05-03 | 江西同和药业股份有限公司 | 一种阿帕他酮关键中间体的制备方法及其应用 |
WO2023078252A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
Family Cites Families (287)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4608A (en) * | 1846-06-27 | Netting-machine | ||
US4448A (en) * | 1846-04-04 | Xjoel | ||
US2065593A (en) * | 1936-12-29 | Water-soluble diazoimino com | ||
FR472489A (fr) | 1914-02-20 | 1914-12-08 | Stas Motor Ges M B H | Bague de garniture métallique pour pistons |
FR803619A (fr) | 1935-03-23 | 1936-10-05 | Ig Farbenindustrie Ag | Acide du type dihydroxystilbène-dicarboxylique et son procédé de préparation |
US2065900A (en) * | 1935-03-23 | 1936-12-29 | Gen Aniline Works Inc | Dihydroxystilbene-dicarboxylic acid and a process of preparing it |
DE637259C (de) | 1935-03-24 | 1936-10-27 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung einer Dioxystilbendicarbonsaeure |
FR803201A (fr) | 1935-07-08 | 1936-09-25 | Ste Ind Chim Bale | Préparation d'acides sulfoniques |
US2071329A (en) * | 1935-08-22 | 1937-02-23 | Solvay Process Co | Method of recovering phthalic anhydride |
DE652772C (de) | 1935-11-07 | 1937-11-08 | I G Farbenindustrie Akt Ges | Verfahren zur Herstellung von N-Dihydroazinen der Anthrachinonreihe |
GB728767A (en) | 1951-10-12 | 1955-04-27 | Wander Ag Dr A | 2-substituted chromone compounds, and a method of making same |
BE633049A (el) | 1962-06-06 | |||
US3251837A (en) * | 1962-09-14 | 1966-05-17 | Pfizer & Co C | Derivatives of 1, 2, 4-benzothiadiazine-1, 1-dioxides |
GB1179019A (en) | 1967-05-23 | 1970-01-28 | Produits Chimique Soc Et | Polynicotinic Esters of Flavonoids |
FR6928M (el) | 1967-11-24 | 1969-05-05 | ||
US3600394A (en) * | 1968-05-17 | 1971-08-17 | Searle & Co | 2-aminoalkyl-3-arylisocarbostyrils |
US3773946A (en) * | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
US3930024A (en) * | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
US3862186A (en) | 1972-12-15 | 1975-01-21 | Bristol Myers Co | Process for the production of cephalexin monohydrate |
FR2244493A1 (en) | 1973-08-09 | 1975-04-18 | Pluripharm | Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis |
DE2349024A1 (de) | 1973-09-26 | 1975-04-10 | Schering Ag | 6beta,7beta-epoxy-1alpha,2alphamethylen-d-homo-4-pregnen-3,20-dione |
IT1050750B (it) | 1975-12-05 | 1981-03-20 | Erba Carlo Spa | Derivati della 3.4 di idro chinazolina |
GB1532682A (en) | 1976-04-27 | 1978-11-22 | Bristol Myers Co | Process for the preparation of cephadroxil |
US4159330A (en) | 1976-11-02 | 1979-06-26 | Carlo Erba S.P.A. | 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation |
US5098903A (en) | 1980-03-07 | 1992-03-24 | Board Of Regents Of The University Of Oklahoma | Diphenylcyclopropyl analogs as antiestrogenic and antitumor agents |
IL64542A0 (en) * | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
JPS60136512A (ja) * | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | 脂質代謝改善剤 |
DE3423166A1 (de) * | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
DE3579888D1 (de) | 1984-11-08 | 1990-10-31 | Sumitomo Pharma | Carbapenemverbindungen und deren herstellung. |
DE3515882A1 (de) * | 1985-05-03 | 1986-11-06 | Dr. Karl Thomae Gmbh, 7950 Biberach | Arzneimittel, enthaltend pyridinone mit antithrombotischen wirkungen und verfahren zu ihrer herstellung |
DE3532279A1 (de) | 1985-09-11 | 1987-03-12 | Bayer Ag | 1,4-benzoxathiin-derivate |
ES2058061T3 (es) | 1985-10-25 | 1994-11-01 | Beecham Group Plc | Derivado de piperidina, su preparacion y su uso como medicamento. |
DE3601417A1 (de) | 1986-01-20 | 1987-07-23 | Nattermann A & Cie | 2'-alkyl-(alkenyl-) substituierte quercetine |
US4663345A (en) | 1986-04-17 | 1987-05-05 | American Home Products Corporation | Etodolac for treatment of gout |
US4825005A (en) * | 1986-08-29 | 1989-04-25 | Ciba-Geigy Corporation | Process for the preparation of aromatic ether and thioether compounds |
DE3784147T2 (de) | 1986-11-24 | 1993-06-03 | Fujisawa Pharmaceutical Co | 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-en-2-carbonsaeure-derivate. |
JPH07118241B2 (ja) | 1987-10-21 | 1995-12-18 | 松下電器産業株式会社 | 器具の蓋開閉装置 |
GB8804058D0 (en) | 1988-02-22 | 1988-03-23 | Fujisawa Pharmaceutical Co | 3-alkenyl-1-azabicyclo(3 2 0)hept-2-ene-2-carboxylic acid compounds |
US4925838A (en) | 1988-03-18 | 1990-05-15 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
US4963544A (en) | 1988-05-23 | 1990-10-16 | Fujisawa Pharmaceutical Company, Ltd. | 3-pyrrolidinylthio-1-azabicyclo[3.2.0]-hept-2-ene-2-carboxylic acid compounds |
GB8926981D0 (en) | 1988-12-23 | 1990-01-17 | Ici Plc | Heterocyclic derivatives |
JPH0741442Y2 (ja) | 1989-01-31 | 1995-09-27 | シャープ株式会社 | 生体用電極保持体 |
KR920701167A (ko) | 1989-07-07 | 1992-08-11 | 에릭 에스. 딕커 | 약제학적 활성 화합물 |
FR2649612A1 (fr) | 1989-07-17 | 1991-01-18 | Rhone Poulenc Sante | Medicaments a base de derives de 1h-benzoxadiazine-4,1,2 nouveaux derives et leurs procedes de preparation |
IE64358B1 (en) | 1989-07-18 | 1995-07-26 | Ici Plc | Diaryl ether heterocycles |
US5332832A (en) | 1989-07-26 | 1994-07-26 | Procter & Gamble Pharmaceuticals, Inc. | Nitrofurantoin crystals |
GB9018134D0 (en) | 1989-09-29 | 1990-10-03 | Ici Plc | Heterocyclic derivatives |
JP3180344B2 (ja) * | 1990-06-05 | 2001-06-25 | 東レ株式会社 | インドール誘導体 |
JP2999579B2 (ja) * | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | Dnaおよびその用途 |
GB9025832D0 (en) | 1990-11-28 | 1991-01-09 | Ashwell Geoffrey J | Novel films for nonlinear optical applications |
IE913866A1 (en) | 1990-11-28 | 1992-06-03 | Ici Plc | Aryl derivatives |
US5126351A (en) * | 1991-01-24 | 1992-06-30 | Glaxo Inc. | Antitumor compounds |
MX9200299A (es) | 1991-02-07 | 1992-12-01 | Roussel Uclaf | Nuevos derivados biciclicos nitrogenados, su procedimiento de preparacion los nuevos compuestos intermedios obtenidos su aplicacion como medicamentos y las composiciones farmaceuticas que los contienen. |
WO1992018123A2 (en) | 1991-04-10 | 1992-10-29 | Octamer, Inc. | A method for inhibition of retroviral replication |
SG64322A1 (en) * | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US5480883A (en) * | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5124337A (en) * | 1991-05-20 | 1992-06-23 | Schering Corporation | N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase |
US5223506A (en) | 1991-06-04 | 1993-06-29 | Glaxo Inc. | Cyclic antitumor compounds |
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
US5474994A (en) | 1992-05-26 | 1995-12-12 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A |
FR2689127B1 (fr) | 1992-03-31 | 1994-05-06 | Adir Cie | Nouvelles 3', 5' -ditertbutyl-4'-hydroxy flavones, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
US7655699B1 (en) | 1992-04-22 | 2010-02-02 | Eisai Inc. | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors |
DE4215587A1 (de) | 1992-05-12 | 1993-11-18 | Bayer Ag | Sulfonylbenzyl-substituierte Benzo- und Pyridopyridone |
DE4215588A1 (de) * | 1992-05-12 | 1993-11-18 | Bayer Ag | Biphenylmethyl-substituierte Pyridone |
GB9218334D0 (en) | 1992-08-28 | 1992-10-14 | Ici Plc | Heterocyclic compounds |
JPH0680656A (ja) | 1992-09-03 | 1994-03-22 | Mitsui Petrochem Ind Ltd | 光学活性エポキシドの製造方法 |
AU5850894A (en) | 1992-12-23 | 1994-07-19 | Procept, Inc. | Novel agents for inhibition of hiv infectivity and use therefor |
JPH0741442A (ja) | 1993-05-21 | 1995-02-10 | Sumitomo Chem Co Ltd | アセチレンアルコール誘導体およびその製造法 |
JPH0761942A (ja) | 1993-06-17 | 1995-03-07 | Sumitomo Chem Co Ltd | フェノール誘導体およびその製造法 |
JPH0725761A (ja) | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
DE69428703T2 (de) * | 1993-07-23 | 2002-05-29 | Zaidan Hojin Biseibutsu | Pyrrolidin derivate |
US5707547A (en) | 1993-08-03 | 1998-01-13 | Sumitomo Chemical Company, Limited | Trans-olefin compounds, method for production thereof, liquid crystal composition containing the same as active ingredient, and liquid crystal element using said composition |
JPH07118241A (ja) | 1993-09-01 | 1995-05-09 | Sumitomo Chem Co Ltd | フェノール誘導体およびその製造法 |
JPH07179380A (ja) | 1993-12-22 | 1995-07-18 | Sumitomo Chem Co Ltd | アルコール誘導体およびその製造法 |
JPH07233109A (ja) | 1994-02-24 | 1995-09-05 | Sumitomo Chem Co Ltd | 光学活性なアルコール誘導体およびその製造法 |
AU680736B2 (en) | 1994-02-25 | 1997-08-07 | Banyu Pharmaceutical Co., Ltd. | Carbapenem derivative |
DE69521500T2 (de) * | 1994-03-08 | 2001-12-13 | Otsuka Pharma Co Ltd | Phosphorsäurediester-derivate |
JPH07247289A (ja) | 1994-03-11 | 1995-09-26 | Mitsui Petrochem Ind Ltd | クロメンオキシド類の製造方法 |
FR2718329B1 (fr) * | 1994-03-21 | 2002-09-20 | Rhone Poulenc Rorer Sa | Lapin transgénique sensibilisé aux dyslipoprotéinémies. |
US6048903A (en) * | 1994-05-03 | 2000-04-11 | Robert Toppo | Treatment for blood cholesterol with trans-resveratrol |
US6168776B1 (en) * | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
GB2292149A (en) | 1994-08-09 | 1996-02-14 | Ferring Res Ltd | Peptide inhibitors of pro-interleukin-1beta converting enzyme |
JP3702493B2 (ja) | 1994-08-12 | 2005-10-05 | 大正製薬株式会社 | キナゾリン−4(3h)−オン誘導体 |
IL115256A0 (en) * | 1994-11-14 | 1995-12-31 | Warner Lambert Co | 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use |
ES2146782T3 (es) | 1994-11-14 | 2000-08-16 | Warner Lambert Co | 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa. |
US5446071A (en) * | 1994-11-18 | 1995-08-29 | Eli Lilly And Company | Methods for lowering serum cholesterol |
JP4140981B2 (ja) * | 1994-12-26 | 2008-08-27 | 東菱薬品工業株式会社 | 再狭窄症及び動脈硬化症治療薬 |
US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
WO1996031206A2 (en) | 1995-04-07 | 1996-10-10 | Warner-Lambert Company | Flavones and coumarins as agents for the treatment of atherosclerosis |
EP0747051B1 (en) | 1995-06-07 | 2002-07-24 | Eli Lilly And Company | Treatment of diseases by inducing BEF-1 transcription factor |
US5922866A (en) * | 1995-08-30 | 1999-07-13 | Otsuka Pharmaceutical Factory, Inc. | Process for preparing quinazolin-4-one derivatives |
WO1997010221A1 (en) | 1995-09-15 | 1997-03-20 | Torrey Pines Institute For Molecular Studies | Synthesis of quinazolinone libraries |
US5783577A (en) | 1995-09-15 | 1998-07-21 | Trega Biosciences, Inc. | Synthesis of quinazolinone libraries and derivatives thereof |
BR9611210A (pt) | 1995-10-23 | 1999-12-28 | Zymogenetics Inc | Composições e processos para tratamento de condições ósseas deficitárias |
RU2135494C1 (ru) | 1995-12-01 | 1999-08-27 | Санкио Компани Лимитед | Гетероциклические соединения и композиция на их основе, проявляющая антагонистическое действие в отношении рецепторов тахикинина |
US5756736A (en) * | 1996-01-26 | 1998-05-26 | Syntex (U.S.A.) Inc. | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative |
US5739330A (en) | 1996-02-05 | 1998-04-14 | Hoechst Celanese Corporation | Process for preparing quinazolones |
WO1997028118A1 (en) | 1996-02-05 | 1997-08-07 | Hoechst Celanese Corporation | Process for preparing anthranilic acids |
US5763608A (en) | 1996-02-05 | 1998-06-09 | Hoechst Celanese Corporation | Process for preparing pyrimidine derivatives |
CN1067070C (zh) | 1996-02-12 | 2001-06-13 | 新泽西州州立大学(拉特格斯) | 用作拓扑异构酶抑制剂的甲氧檗因类似物 |
KR20000022040A (ko) | 1996-06-20 | 2000-04-25 | 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 | 약학적 활성 제제를 제공하기 위한 화합물, 방법 및 그의 용도 |
US5854264A (en) * | 1996-07-24 | 1998-12-29 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
KR100213895B1 (ko) * | 1996-10-14 | 1999-08-02 | 박원훈 | 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물 |
DE19651099A1 (de) | 1996-12-09 | 1998-06-10 | Consortium Elektrochem Ind | Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung |
IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
US6613722B1 (en) | 1997-03-07 | 2003-09-02 | Exxon Chemical Patents Inc. | Lubricating composition |
JPH10287678A (ja) | 1997-04-11 | 1998-10-27 | Kyowa Hakko Kogyo Co Ltd | ピラノアジン誘導体 |
AR012634A1 (es) | 1997-05-02 | 2000-11-08 | Sugen Inc | Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion |
US5908861A (en) * | 1997-05-13 | 1999-06-01 | Octamer, Inc. | Methods for treating inflammation and inflammatory disease using pADPRT inhibitors |
NZ501650A (en) | 1997-05-13 | 2001-11-30 | Octamer Inc | Use of a pADPRT inhibitory compound that is not 3-aminobenzamide to treat inflammation and inflammatory diseases in mammals |
RU2209066C2 (ru) | 1997-06-02 | 2003-07-27 | Янссен Фармацевтика Н.В. | Производные (имидазол-5-ил)метил-2-хинолинона в качестве ингибиторов пролиферации клеток гладкой мышцы |
IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
TW450964B (en) | 1997-08-29 | 2001-08-21 | Takeda Schering Plough Animal | Triazine derivatives, their production and use |
US6635642B1 (en) * | 1997-09-03 | 2003-10-21 | Guilford Pharmaceuticals Inc. | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same |
US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
US6239114B1 (en) * | 1997-09-26 | 2001-05-29 | Kgk Synergize | Compositions and methods for treatment of neoplastic diseases with combinations of limonoids, flavonoids and tocotrienols |
ATE404539T1 (de) | 1997-10-02 | 2008-08-15 | Eisai R&D Man Co Ltd | Kondensierte pyridinderivate |
EP1032381B1 (en) * | 1997-10-28 | 2003-09-03 | Korea Institute Of Science And Technology | Naringin and naringenin as preventive or treating agent for hepatic diseases |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
DE19756388A1 (de) * | 1997-12-18 | 1999-06-24 | Hoechst Marion Roussel De Gmbh | Substituierte 2-Aryl-4-amino-chinazoline |
DE69926729T2 (de) * | 1998-01-08 | 2006-06-08 | Aventis Pharmaceuticals Inc. | Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert |
US6414037B1 (en) * | 1998-01-09 | 2002-07-02 | Pharmascience | Pharmaceutical formulations of resveratrol and methods of use thereof |
CN100374159C (zh) | 1998-03-17 | 2008-03-12 | 中外制药株式会社 | 一种包含il-6拮抗剂活性成分的炎性肠道疾病的预防或治疗剂 |
US6022901A (en) * | 1998-05-13 | 2000-02-08 | Pharmascience Inc. | Administration of resveratrol to prevent or treat restenosis following coronary intervention |
SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
KR20010079922A (ko) | 1998-09-24 | 2001-08-22 | 미우라 아키라 | 하이드록시플라본 유도체 |
CN1148188C (zh) | 1998-10-19 | 2004-05-05 | 卫材株式会社 | 镇痛剂 |
WO2000023073A1 (en) * | 1998-10-20 | 2000-04-27 | Korea Institute Of Science And Technology | Bioflavonoids as plasma high density lipoprotein level increasing agent |
US6433187B1 (en) | 1998-12-17 | 2002-08-13 | Tularik Inc. | Certain polycyclic compounds useful as tubulin-binding agents |
US6291456B1 (en) * | 1998-12-30 | 2001-09-18 | Signal Pharmaceuticals, Inc. | Compounds and methods for modulation of estrogen receptors |
US6399633B1 (en) | 1999-02-01 | 2002-06-04 | Aventis Pharmaceuticals Inc. | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
ATE266036T1 (de) | 1999-03-15 | 2004-05-15 | Abbott Lab | 6-o-substitutierte makroliden mit antibakterieller wirkung |
US6969720B2 (en) * | 1999-03-17 | 2005-11-29 | Amr Technology, Inc. | Biaryl substituted purine derivatives as potent antiproliferative agents |
US6054435A (en) * | 1999-03-19 | 2000-04-25 | Abbott Laboratories | 6-O-substituted macrolides having antibacterial activity |
ES2287016T3 (es) | 1999-04-28 | 2007-12-16 | Sanofi-Aventis Deutschland Gmbh | Derivados de diaril-acido como ligandos del receptor ppar. |
US6835755B1 (en) | 1999-06-24 | 2004-12-28 | University Of Pretoria | Naphthoquinone derivatives and their use in the treatment and control of tuberculosis |
DE19934799B4 (de) | 1999-07-28 | 2008-01-24 | Az Electronic Materials (Germany) Gmbh | Chiral-smektische Flüssigkristallmischung und ihre Verwendung in Aktivmatrix-Displays mit hohen Kontrastwerten |
JP2001131151A (ja) | 1999-11-02 | 2001-05-15 | Shionogi & Co Ltd | オレフィン誘導体の新規用途 |
JP5278983B2 (ja) | 1999-11-17 | 2013-09-04 | 塩野義製薬株式会社 | アミド化合物の新規用途 |
CA2393297C (en) * | 1999-12-06 | 2010-10-05 | Welichem Biotech Inc. | Polyhydroxystilbenes as antipsoriatic agents and protein kinase inhibitors |
FR2804679B1 (fr) | 2000-02-07 | 2002-04-26 | Clariant France Sa | Nouveaux composes phenoliques derives des dialcoxyethanals, leur procede de preparation et leur application |
ES2225475T3 (es) | 2000-02-17 | 2005-03-16 | Appleton Papers Inc. | Procedimiento para preparar alcoxi- o aroxietanos. |
WO2001083456A1 (fr) | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'heteroaryle condenses |
US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
US6548694B2 (en) | 2000-05-23 | 2003-04-15 | Hoffman-La Roche Inc. | N-(4-carbamimidoyl-phenyl)-glycine derivatives |
WO2003024441A1 (fr) | 2001-09-14 | 2003-03-27 | Shionogi & Co., Ltd. | Nouvelle utilisation de composes tricycliques |
JP2001335476A (ja) | 2000-05-29 | 2001-12-04 | Shionogi & Co Ltd | 三環化合物の新規用途 |
US6479499B1 (en) | 2000-06-28 | 2002-11-12 | National Science Council | 2-phenyl-4-quinazolinone compounds, 2-phenyl-4-alkoxy-quinazoline compounds and their pharmaceutical compositions |
US20020025301A1 (en) | 2000-07-04 | 2002-02-28 | Sylke Haremza | Novel flavonoids and their use in cosmetic and dermatological preparations |
US6541522B2 (en) * | 2000-08-16 | 2003-04-01 | Insmed Incorporated | Methods of using compositions containing hypotriglyceridemically active stilbenoids |
US7723303B2 (en) | 2000-08-24 | 2010-05-25 | The Regents Of The University Of California | Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
AU9650201A (en) | 2000-10-02 | 2002-04-15 | Molecular Probes Inc | Reagents for labeling biomolecules having aldehyde or ketone moieties |
CA2356544C (en) | 2000-10-03 | 2006-04-04 | Warner-Lambert Company | Pyridotriazines and pyridopyridazines |
NZ525591A (en) * | 2000-10-05 | 2004-04-30 | Fujisawa Pharmaceutical Co | Benzamide compounds as Apo B secretion inhibitors |
JP2004532799A (ja) * | 2000-10-11 | 2004-10-28 | エスペリオン セラピューティクス,インコーポレイテッド | コレステロール管理および関連用途のためのスルフィド化合物およびジスルフィド化合物ならびにそれらを含む組成物 |
CA2425678A1 (en) * | 2000-10-11 | 2002-04-18 | Jean-Louis H. Dasseux | Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses |
PL361053A1 (en) | 2000-10-19 | 2004-09-20 | Merck & Co,Inc. | Estrogen receptor modulators |
EP1348711B1 (en) * | 2000-11-30 | 2018-06-13 | Canon Kabushiki Kaisha | Luminescent element and display |
CA2430951A1 (en) * | 2000-12-07 | 2002-06-13 | Cv Therapeutics, Inc. | Substituted 1, 3, 5-triazines and pyrimidines as abca-1 elevating compounds against coronary artery disease or atherosclerosis |
KR100472694B1 (ko) * | 2000-12-30 | 2005-03-07 | 한국생명공학연구원 | 플라바논 유도체 및 이를 포함하는 혈중 지질 농도 관련질환의 예방 및 치료용 조성물 |
JP2002249483A (ja) | 2001-02-21 | 2002-09-06 | Koei Chem Co Ltd | アリール置換複素環式化合物の製造法 |
WO2002074307A1 (en) | 2001-03-16 | 2002-09-26 | Novogen Research Pty Ltd | Treatment of restenosis |
JP4334233B2 (ja) * | 2001-04-11 | 2009-09-30 | アセロジエニクス・インコーポレイテツド | プロブコールモノエステルによって血漿hdlコレステロールレベルを上昇させ、hdlの機能性を改善するための方法 |
ES2333412T3 (es) | 2001-05-25 | 2010-02-22 | Bristol-Myers Squibb Company | Derivados de hidantoina como inhibidores de metaloproteinasas de matriz. |
WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
US7173128B2 (en) * | 2001-08-13 | 2007-02-06 | Ciba Specialty Chemicals Corporation | Ultraviolet light absorbers |
EP1419770A4 (en) * | 2001-08-24 | 2005-08-03 | Shionogi & Co | AGENT ACC L RATION OF THE EXPRESSION OF APO AI |
US8124625B2 (en) * | 2001-09-14 | 2012-02-28 | Shionogi & Co., Ltd. | Method of enhancing the expression of apolipoprotein AI using olefin derivatives |
US7429593B2 (en) * | 2001-09-14 | 2008-09-30 | Shionogi & Co., Ltd. | Utilities of amide compounds |
US6835469B2 (en) * | 2001-10-17 | 2004-12-28 | The University Of Southern California | Phosphorescent compounds and devices comprising the same |
US7166368B2 (en) | 2001-11-07 | 2007-01-23 | E. I. Du Pont De Nemours And Company | Electroluminescent platinum compounds and devices made with such compounds |
US7250512B2 (en) | 2001-11-07 | 2007-07-31 | E. I. Du Pont De Nemours And Company | Electroluminescent iridium compounds having red-orange or red emission and devices made with such compounds |
US6541045B1 (en) * | 2002-01-04 | 2003-04-01 | Nutraceutical Corporation | Herbal composition and method for combating inflammation |
DE60328461D1 (de) | 2002-01-28 | 2009-09-03 | Ube Industries | Verfahren zur herstellung eines chinazolin-4-onderivats |
US20050176796A1 (en) | 2002-02-19 | 2005-08-11 | D'alessio Roberto | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents |
GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
NZ556545A (en) | 2002-03-22 | 2009-03-31 | Novartis Ag | Combination comprising a beta-hydroxy-beta-methylglutaryl-co-enzyme-A reductase inhibitor and a glucagon-like peptide-1 agonist |
MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
WO2003106435A1 (en) * | 2002-06-18 | 2003-12-24 | Sankyo Company, Limited | Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof |
KR20040001144A (ko) * | 2002-06-27 | 2004-01-07 | 김대경 | 신규한 적혈구 세포질형 포스포리파아제 에이 투 효소,그에 대한 항체, 이들의 용도 및 제조 방법 |
US20050080021A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives of stilbenes, polyphenols and flavonoids for the treatment of cardiovascular disorders |
US20050080024A1 (en) * | 2002-08-15 | 2005-04-14 | Joseph Tucker | Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
US20040033480A1 (en) * | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
CN1671639A (zh) | 2002-08-23 | 2005-09-21 | 康涅狄格大学 | 新型联苯大麻素和类似联苯的大麻素 |
WO2004019933A1 (en) | 2002-08-30 | 2004-03-11 | Pharmacia & Upjohn Company | Method of preventing or treating atherosclerosis or restenosis |
EP1398032A1 (en) | 2002-09-10 | 2004-03-17 | PheneX Pharmaceuticals AG | 4-Oxo-quinazolines as LXR nuclear receptor binding compounds |
EP1407774A1 (en) * | 2002-09-10 | 2004-04-14 | LION Bioscience AG | 2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds |
AU2003284001A1 (en) | 2002-10-07 | 2004-05-04 | Bristol-Myers Squibb Company | Triazolone and triazolethione derivatives |
EP1553947A4 (en) | 2002-10-21 | 2006-11-29 | Bristol Myers Squibb Co | QUINAZOLINONES AND DERIVATIVES THEREOF AS FACTOR XA INHIBITORS |
WO2004039795A2 (en) | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Amide compounds for the treatment of hyperlipidemia |
WO2004041755A2 (en) | 2002-11-04 | 2004-05-21 | Nps Pharmaceuticals, Inc. | Quinazolinone compounds as calcilytics |
EP1418164A1 (en) | 2002-11-07 | 2004-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New stilbene derivatives and their use as aryl hydrocarbon receptor ligand antagonists |
MXPA05005028A (es) * | 2002-11-18 | 2005-08-03 | Hoffmann La Roche | Diazinopirimidinas. |
EP1562956A4 (en) | 2002-11-22 | 2007-10-10 | Japan Tobacco Inc | HETEROCYCLES CONTAINING FUSED BICYCLIC NITROGEN |
ES2270154T3 (es) * | 2002-12-13 | 2007-04-01 | F. Hoffmann-La Roche Ag | Derivados de 3h-quinazolin-4-ona. |
ITRM20020629A1 (it) | 2002-12-19 | 2004-06-20 | Sigma Tau Ind Farmaceuti | Uso di acidi alfa-feniltiocarbossilici e alfa-fenilossicarbossilici ad attivita' ipoglicemizzante e/o ipolipidemizzante. |
WO2004058717A1 (en) * | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
JP2004203751A (ja) | 2002-12-24 | 2004-07-22 | Pfizer Inc | 置換6,6−ヘテロ二環式誘導体 |
CA2512000C (en) * | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
WO2004065392A1 (en) * | 2003-01-24 | 2004-08-05 | Smithkline Beecham Corporation | Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands |
WO2004072042A2 (en) | 2003-02-12 | 2004-08-26 | Carex S.A. | Quinoline derivative and their use for modulation of lxr activity |
US7547794B2 (en) * | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
CA2520323C (en) | 2003-04-09 | 2013-07-09 | Exelixis, Inc. | Tie-2 modulators and methods of use |
JP2004307440A (ja) | 2003-04-10 | 2004-11-04 | Kyorin Pharmaceut Co Ltd | 2−アミノ‐1,3‐プロパンジオール誘導体とその付加塩 |
ES2386161T3 (es) | 2003-04-16 | 2012-08-10 | Bristol-Myers Squibb Company | Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima |
DE602004025803D1 (de) | 2003-06-06 | 2010-04-15 | Arexis Ab | Verwendung von kondensierten heterozyklischen verbindungen als scce-hemmern zur behandlung von hautzuständen |
ES2389258T3 (es) | 2003-06-17 | 2012-10-24 | Millennium Pharmaceuticals, Inc. | Composiciones y métodos para inhibir TGF-s |
EP1637523A4 (en) | 2003-06-18 | 2009-01-07 | Ube Industries | PROCESS FOR PRODUCING A PYRIMIDIN-4-ONE COMPOUND |
US20050043300A1 (en) * | 2003-08-14 | 2005-02-24 | Pfizer Inc. | Piperazine derivatives |
US20050096391A1 (en) | 2003-10-10 | 2005-05-05 | Per Holm | Compositions comprising fenofibrate and rosuvastatin |
CA2541590A1 (en) | 2003-10-10 | 2005-04-21 | Resverlogix Corp. | Treatment of diseases associated with the egr-1 enhancer element |
RU2006112343A (ru) | 2003-10-28 | 2007-12-10 | Редди Юс Терапеутикс, Инк. (Us) | Гетероциклические соединения и способы их получения и применения |
JP2007517071A (ja) | 2003-12-19 | 2007-06-28 | メルク エンド カムパニー インコーポレーテッド | 有糸分裂キネシン阻害剤 |
US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
AU2005247808B2 (en) * | 2004-05-31 | 2011-02-10 | Msd K.K. | Quinazoline derivative |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
WO2006012577A2 (en) | 2004-07-22 | 2006-02-02 | Bayer Pharmaceuticals Corporation | Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake |
US20070218155A1 (en) * | 2004-08-20 | 2007-09-20 | Kuhrts Eric H | Methods and compositions for treating dyslipidaemia |
EP1838296B1 (en) * | 2004-10-20 | 2012-08-08 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
EP1844023A1 (en) | 2004-12-31 | 2007-10-17 | Sk Chemicals Co., Ltd. | Quinazoline derivatives for the treatment and prevention of diabetes and obesity |
CR9465A (es) | 2005-03-25 | 2008-06-19 | Surface Logix Inc | Compuestos mejorados farmacocineticamente |
EP2314295B1 (en) * | 2005-07-29 | 2015-01-28 | Resverlogix, Inc | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
US8163770B2 (en) | 2005-10-27 | 2012-04-24 | Msd. K. K. | Benzoxathiin derivative |
CA2634491A1 (en) | 2005-12-21 | 2007-06-28 | Painceptor Pharma Corporation | Compositions and methods for modulating gated ion channels |
ES2402865T3 (es) | 2006-05-12 | 2013-05-09 | Pharmathen S.A. | Formulación farmacéutica que contiene fluvastatina |
US20080085911A1 (en) | 2006-10-10 | 2008-04-10 | Reliant Pharmaceuticals, Inc. | Statin and omega-3 fatty acids for reduction of apo-b levels |
US20100249161A1 (en) | 2006-11-15 | 2010-09-30 | Anders Klarskov Petersen | 2- ( 2 -hydroxyphenyl) -quinazolin-4-ones useful for treating obesity and diabetes |
JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用 |
US8053440B2 (en) | 2007-02-01 | 2011-11-08 | Resverlogix Corporation | Compounds for the prevention and treatment of cardiovascular diseases |
ES2308916B1 (es) | 2007-03-22 | 2009-10-29 | Consejo Superior De Investigaciones Cientificas | Compuesto inhibidor dual de las enzimas pde7 y/o pde4, composiciones farmaceuticas y sus aplicaciones. |
EP2005941A3 (de) | 2007-06-01 | 2009-04-01 | Henkel AG & Co. KGaA | Zellverjüngende Zusammensetzungen |
WO2008152471A1 (en) | 2007-06-12 | 2008-12-18 | Coley Pharmaceutical Group, Inc. | Quinazoline derivative useful as toll-like receptor antagonist |
MX2009013781A (es) | 2007-06-21 | 2010-02-01 | Irm Llc | Inhibidores de cinasa de proteina y metodos para el uso de los mismos. |
EP2239264A4 (en) | 2007-12-28 | 2012-01-11 | Mitsubishi Tanabe Pharma Corp | ANTITUMOR AGENT |
PT2346837E (pt) | 2008-06-26 | 2015-04-02 | Resverlogix Corp | Métodos de preparação de derivados de quinazolinona |
EP2324022A1 (de) | 2008-08-05 | 2011-05-25 | Boehringer Ingelheim International GmbH | Substituierte naphthyridine und ihre verwendung als arzneimittel |
CN102171240A (zh) | 2008-10-06 | 2011-08-31 | 卡罗勒斯治疗公司 | 治疗炎症的方法 |
EP2362876B1 (en) | 2008-10-30 | 2013-12-11 | Circomed LLC | Thienotriazolodiazepine derivatives active on apo a |
WO2010056910A2 (en) | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
ES2542835T3 (es) | 2009-01-08 | 2015-08-12 | Resverlogix Corporation | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
AU2010220374A1 (en) | 2009-03-06 | 2011-09-01 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
BRPI1009315B8 (pt) | 2009-03-18 | 2021-05-25 | Resverlogix Corp | composto anti-flamatórios e suas composições farmacêuticas |
TR201818390T4 (tr) | 2009-04-22 | 2019-01-21 | Resverlogix Corp | Yeni̇ anti̇-i̇nflamatuvar ajanlar |
EP2424521A4 (en) | 2009-04-29 | 2015-03-04 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE |
ES2353093B1 (es) | 2009-05-20 | 2012-01-03 | Consejo Superior De Investigaciones Científicas (Csic) | Uso de derivados de quinazolinas y sus composiciones farmacéuticas en enfermedades neurodegenerativas. |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
DE102010048800A1 (de) | 2010-10-20 | 2012-05-10 | Merck Patent Gmbh | Chinoxalinderivate |
GB201018147D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Method of treatment |
AR084070A1 (es) | 2010-12-02 | 2013-04-17 | Constellation Pharmaceuticals Inc | Inhibidores del bromodominio y usos de los mismos |
JP2014505732A (ja) | 2011-02-16 | 2014-03-06 | ピヴォタル セラピューティクス インコーポレイテッド | 心血管疾患において用いるための、スタチンおよびω3脂肪酸(EPA、DHAおよびDPA) |
WO2012174487A2 (en) | 2011-06-17 | 2012-12-20 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
CA2862895A1 (en) | 2011-09-30 | 2013-04-04 | Kineta, Inc. | Anti-viral compounds |
PL2773354T3 (pl) | 2011-11-01 | 2019-12-31 | Resverlogix Corp. | Doustna formulacja o natychmiastowym uwalnianiu dla podstawowych chinazolinów |
US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281398A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
US20130281399A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
WO2013184878A1 (en) | 2012-06-06 | 2013-12-12 | Constellation Pharmaceuticals, Inc. | Benzo [b] isoxazoloazepine bromodomain inhibitors and uses thereof |
NZ707276A (en) | 2012-10-15 | 2016-02-26 | Resverlogix Corp | Compounds useful in the synthesis of benzamide compounds |
CA2886973C (en) | 2012-10-15 | 2017-08-15 | Albemarle Corporation | Processes for the synthesis of 2-amino-4,6-dimethoxybenzamide and other benzamide compounds |
US9073878B2 (en) | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
CA2895905A1 (en) | 2012-12-21 | 2014-06-26 | Zenith Epigenetics Corp. | Novel heterocyclic compounds as bromodomain inhibitors |
WO2014110090A1 (en) | 2013-01-08 | 2014-07-17 | Jerome Schentag | Activation of the endogenous ileal brake hormone pathway for organ regeneration and related compositions, methods of treatment, diagnostics, and regulatory systems |
AU2014223990A1 (en) | 2013-02-28 | 2015-09-10 | Washington University | Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors |
US9675697B2 (en) | 2013-03-11 | 2017-06-13 | The Regents Of The University Of Michigan | BET bromodomain inhibitors and therapeutic methods using the same |
US9695179B2 (en) | 2013-03-14 | 2017-07-04 | Convergene Llc | Methods and compositions for inhibition of bromodomain-containing proteins |
CN105164276B (zh) | 2013-03-27 | 2020-01-14 | 豪夫迈·罗氏有限公司 | 用于预测对于治疗的响应性的遗传标记 |
TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類 |
EP3035934A4 (en) | 2013-08-21 | 2017-04-26 | Resverlogix Corp. | Compositions and therapeutic methods for accelerated plaque regression |
JP2016528276A (ja) | 2013-08-21 | 2016-09-15 | レスバーロジックス コーポレイション | プラーク退縮を促進するための組成物及び治療法 |
US9814728B2 (en) | 2013-09-20 | 2017-11-14 | Saint Louis University | Inhibition of DUX4 expression using bromodomain and extra-terminal domain protein inhibitors (BETi) |
EP3689420A1 (en) | 2014-01-23 | 2020-08-05 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Icariin derivatives for use in treating myelodysplasia syndrome |
ES2825675T3 (es) | 2014-07-30 | 2021-05-17 | Hoffmann La Roche | Marcadores genéticos para predecir la reactividad al tratamiento con un agente que aumenta las HDL o que imita las HDL |
WO2016123054A2 (en) | 2015-01-26 | 2016-08-04 | The University Of North Carolina At Chapel Hill | Kinase drug combinations and methods of use thereof |
US20180104232A1 (en) | 2015-03-12 | 2018-04-19 | The University Of Chicago | Methods for determining prognosis for breast cancer patients |
US10111885B2 (en) | 2015-03-13 | 2018-10-30 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
JP2018516884A (ja) | 2015-05-08 | 2018-06-28 | プレジデント アンド フェローズ オブ ハーバード カレッジ | コルチスタチン誘導体による治療に対する患者の標的化選択 |
AU2016276963C1 (en) | 2015-06-12 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
CN106265679A (zh) | 2015-06-28 | 2017-01-04 | 复旦大学 | 溴结构域蛋白抑制剂在制备抗hiv-1潜伏治疗药物中的用途 |
US20180200261A1 (en) | 2015-07-20 | 2018-07-19 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2017037567A1 (en) | 2015-09-03 | 2017-03-09 | Pfizer Inc. | Regulators of frataxin |
US9896663B2 (en) | 2016-03-11 | 2018-02-20 | Peter Maccallum Cancer Institute | Leukaemia stem cell line, its method of production and uses thereof |
WO2017192691A1 (en) | 2016-05-03 | 2017-11-09 | Biogen Ma Inc. | Cell culture containing bromodomain inhibitors |
CN106176753A (zh) | 2016-07-15 | 2016-12-07 | 南方医科大学 | Rvx‑208作为hiv‑1潜伏感染逆转剂的应用 |
CN110049981A (zh) | 2016-12-09 | 2019-07-23 | 苏州科睿思制药有限公司 | 一种溴结构域蛋白抑制剂药物的晶型及其制备方法和用途 |
-
2007
- 2007-02-01 US US11/670,238 patent/US8053440B2/en active Active
- 2007-02-01 KR KR1020097017716A patent/KR101444489B1/ko active IP Right Grant
- 2007-02-01 MX MX2009008099A patent/MX2009008099A/es active IP Right Grant
- 2007-02-01 AU AU2007345526A patent/AU2007345526B2/en active Active
- 2007-02-01 CN CN2007800523498A patent/CN101641339B/zh active Active
- 2007-02-01 PL PL07710597T patent/PL2118074T3/pl unknown
- 2007-02-01 EP EP07710597.1A patent/EP2118074B1/en active Active
- 2007-02-01 JP JP2009547497A patent/JP5236664B2/ja active Active
- 2007-02-01 ES ES07710597.1T patent/ES2454966T3/es active Active
- 2007-02-01 SI SI200731438T patent/SI2118074T1/sl unknown
- 2007-02-01 NZ NZ579355A patent/NZ579355A/en unknown
- 2007-02-01 WO PCT/CA2007/000146 patent/WO2008092231A1/en active Application Filing
- 2007-02-01 PT PT77105971T patent/PT2118074E/pt unknown
- 2007-02-01 CA CA2676984A patent/CA2676984C/en active Active
- 2007-02-01 DK DK07710597.1T patent/DK2118074T3/en active
-
2010
- 2010-03-22 HK HK10102977.1A patent/HK1136283A1/xx unknown
-
2011
- 2011-09-23 US US13/243,776 patent/US8889698B2/en active Active
-
2014
- 2014-03-21 CY CY20141100220T patent/CY1115236T1/el unknown
- 2014-10-14 US US14/513,281 patent/US9199990B2/en active Active
-
2015
- 2015-10-26 US US14/922,645 patent/US20160106750A1/en not_active Abandoned
-
2017
- 2017-09-20 US US15/710,200 patent/US10532054B2/en active Active
-
2019
- 2019-12-09 US US16/707,559 patent/US20200352946A1/en not_active Abandoned
-
2021
- 2021-06-01 US US17/335,960 patent/US20210361656A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1115236T1 (el) | Ενωσεις για την προληψη και τη θεραπεια των καρδιαγγειακων παθησεων | |
CY1116260T1 (el) | Μεθοδοι παρασκευης παραγωγων κιναζολινονης | |
CY1119901T1 (el) | Αναστολεις απομεθυλασων ιστονων | |
CY1124446T1 (el) | Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης | |
CY1118823T1 (el) | Παραγωγα πυριδινης και πυραζινης για την θεραπευτικη αντιμετωπιση της χρονιας αποφρακτικης πνευμονοπαθειας | |
CY1123945T1 (el) | Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες | |
CY1121695T1 (el) | Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit | |
CY1113757T1 (el) | Παραγωγα πιπεριδινης και πιπεραζινης για τη θεραπεια ογκων | |
CY1124742T1 (el) | 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv | |
CY1124959T1 (el) | Αναστολεις λυσινης ειδικης απομεθυλασης-1 | |
CY1121593T1 (el) | Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων | |
CY1119123T1 (el) | Δις-αρυλοσυζευγμενες αρυλοτριαζολονες και η χρηση τους | |
CY1116940T1 (el) | Φλυκταινες εμπλουτισμενες σε φωσφολιπιδιο που φερουν παραγοντα ιστου εχουσες αιμοστατικες δραστικοτητες και χρησεις αυτων | |
CY1114507T1 (el) | Συγχωνευμενη αμινο πυριδινη ως hsp90 αναστολεας | |
CY1111757T1 (el) | Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α | |
CY1109644T1 (el) | 2,4-διαμινο-πυριμιδινες ως αναστολεις audora | |
CY1118143T1 (el) | Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1 | |
CY1116700T1 (el) | Παρασκευη συνθετικου χολικου οξεος | |
CY1112495T1 (el) | Κυτταροτοξικοι παραγοντες που περιλαμβανουν νεα παραγωγα τομαϋμυκινης | |
CY1115403T1 (el) | Αλκυλαμινο-υποκατεστημενες δικυανοπυριδινες και προφαρμακα τυπου εστερα αμινοξεος αυτων | |
EA201000777A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
CY1107215T1 (el) | Υποκατεστημενα παραγωγα πυριδινυλιου και πυριμιδινυλιου ως διαμορφωτες του μεταβολισμου και η θεραπεια των σχετικων με αυτον διαταραχων | |
EA201001143A1 (ru) | Активаторы прокаспаз "исполнителей" 3, 6 и 7 | |
CY1112813T1 (el) | 4-(4-κυανο-2-θειοαρυλ)διϋδροπυριμιδινονες και η χρηση αυτων | |
CY1115585T1 (el) | Κρυσταλλικες μορφες του αλατος του νατριου της 5-αμινο-2,3-διυδροφθαλαζιν-1,4-διονης, οι οποιες περιεχουν φαρμακευτικα σκευασματα και διαδικασιες για την παρασκευη τους |